For over 25 years, Cuba's Center of Molecular Immunology had been working on producing a vaccine that could treat non-small cell lung cancer.
Cimavax is that vaccine and has proven to be one of the most effective ways to treat lung cancer that is in the late stages (stage IIIB to IV).
The vaccine works by targeting the protein called epidermal growth factor (EGF).
Many cancers will force the body to produce large amounts of EGF which makes the cells grow and divide and unable to control. Cimavax is partially composed of EGF and tells the body to create antibodies which identify and bind to the EGF stopping it from being able to attach to the receptors of the cancer cells. By doing this, Cimavax will cut off the signal that the cancer sends to its cell to grow and divide which in return will slow down the growth of the lung cancer. The Cimavax vaccine does not prevent lung cancer, but it can change your condition from life threatening to a chronic and manageable condition.
CimaVax-EGF is the first therapeutic cancer vaccine developed to target lung cancer. The vaccine was the result of a 25-year research project at Cuba’s Center of Molecular Immunology.